Posts for Ticker ‘CELG’

Top 10 Analyst Upgrades & Downgrades (ATK, CELG, NTAP, NVLS, WMT, ATHN, ARNA, BK, GENZ, Q)

These are the top 10 analyst upgrades, downgrades, and initiations we have seen early this Monday morning:

Alliant Techsystems (ATK) Started as Buy at Jefferies.
Celgene (CELG) raised to Outperform at R.W.Baird.
NetApp (NTAP) raised to Conviction Buy List at Goldman Sachs
Novellus (NVLS) Raised to Outperform at Credit Suisse.
Wal-Mart (WMT) Started as Overweight at HSBC.
Athenahealth (ATHN) started as Sell at Citigroup.
Arena Pharmaceuticals (ARNA) cut to Market Perform at Leerink Swann.
Bank of New York Mellon (BK) Cut to Neutral at Goldman Sachs.
Genzyme (GENZ) Cut to Perform at Oppenheimer.
Qwest (Q) Cut to Conviction Sell List, but was already a Sell, at Goldman Sachs.

JON C. OGG

Top Day Trader Alerts (MEDX, ISRG, OREX, CELG, EBAY, SNDK, PSUN, QCOM)

The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis at VSInvestor.com:

Medarex Inc. (Nasdaq: MEDX) shares are up about 90 percent after Bristol-Myers Squibb Co. (NYSE: BMY) said it plans to buy the company for $2.4 billion, or $16 a share.

Pacific Sunwear of California Inc. (Nasdaq: PSUN) shares are getting hit on a second-quarter warning.

Orexigen Therapeutics Inc. (Nasdaq: OREX) shares are falling, and are among the most actively traded Nasdaq stocks after the company proposed a 9 million-share offering.

Celgene Corp. (Nasdaq: CELG) shares are up more than 10 percent on stronger-than-expected revenue and net procedure sales growth.

Intuitive Surgical Inc. (Nasdaq: ISRG) shares are up strongly on better-than-expected earnings and strong procedure growth guidance.

eBay Inc. (Nasdaq: EBAY) shares are up after beating quarterly expectations and guiding third-quarter revenue slightly higher.

SanDisk Corp. (Nasdaq: SNDK) shares are down after it beat Q2 expectations, but gave cautious guidance.

Qualcomm Inc. (Nasdaq: QCOM) shares are falling after it beat expectations, but only guided in-line, amid analyst concerns about average selling prices.

– The 24/7 Wall St. Team

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early afternoon Thursday after Japan okayed one of the company’s human growth hormones, the first approval in Japan of a generic biotech drug.  With the recent talks of President Obama wanting generic biologics, the approval process in Japan is probably not an isolated event and should not be ignored for broader implications.
Read More »

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend.   This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies:  Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Top Analyst Upgrades (ANDE, CAT, CELG, CLX, DNDN)

money-stack-image45It is actually looking pretty thin out there in the land of analyst upgrades.  These are the few upgrades and positive research calls we have seen from Wall Street this Wednesday morning with about two hours until the market open:

Andersons (ANDE) Raised to Buy at Piper Jaffray.
Caterpillar (CAT) Raised to Overweight at JPMorgan.
Celgene (CELG) Raised to Outperform at Bernstein.
Clorox (CLX) Started as Outperform at RBC.
Dendreon (DNDN) Raised to Buy at Merriman Curhan Ford.

JON C. OGG

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks.  The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and some traders and investors may be using this as a preview for what lies ahead at the American Society of Clinical Oncology (ASCO) annual meeting in a month.  The following companies which are presenting data:

  • Allos Therapeutics, Inc. (NASDAQ: ALTH)
  • Amgen (NASDAQ: AMGN)
  • ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
  • Array BioPharma, Inc. (NASDAQ: ARRY)
  • AstraZeneca’s (NYSE: AZN) Medimmune unit
  • Biogen Idec Inc. (NASDAQ: BIIB)
  • Celgene Corporation (NASDAQ: CELG)
  • Curis, Inc. (NASDAQ: CRIS)
  • Immunomedics, Inc. (Nasdaq: IMMU)
  • ImmunoGen, Inc. (Nasdaq: IMGN)
  • Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
  • Medarex, Inc. (Nasdaq: MEDX)
  • Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • Pfizer (NYSE: PFE)
  • Pharmacyclics, Inc. (NASDAQ: PCYC)
  • SuperGen Inc. (NASDAQ:SUPG)
  • Telik, Inc. (Nasdaq: TELK)
  • Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)

You can see a full summary of the data being presented at BioHealthInvestor.com site.  There will be others presenting data this weekend, and these were from the press releases of the meeting ahead of time.

JON C. OGG

Top Pre-Market Analyst Upgrades & Downgrades (COF, CELG, ROCK, MOD, SNN, AFL, AMX, SPSS, VQ, WMS)

money-stack-pic2These are ten of the top pre-market analyst calls for upgrades and downgrades we have seen from Wall Street this Wednesday morning with more than two hours until the market opens:

  • Capital One (COF) Raised to Market Perform at FBR.
  • Celgene (CELG) Started as Outperform at Oppenheimer.
  • Gibralter Industries (ROCK) Raised to Neutral at Baird.
  • Modine Manufacturing Co. (MOD)  Raised to Neutral at Baird.
  • Smith & Nephew (SNN) Raised to Buy at Citigroup.
  • AFLAC (AFL) Cut to Market Perform at FBR.
  • America Movil SA (AMX) Cut to Neutral at JPMorgan.
  • SPSS (SPSS) Cut to Neutral at Baird.
  • Venoco, Inc. (VQ) Cut to Underweight at JPMorgan.
  • WMS Industries Inc. (WMS) Cut to Neutral at JPMorgan.

JON C. OGG

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Biogen_logoBiogen Idec Inc. (NASDAQ: BIIB) is set to report earnings on Friday morning.  What many investors probably want to know is if these results — or more importantly its guidance — show that this company will be an acquisition target by a larger rival.

Read More »

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

Money_stack_picThere may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions.  The FT reported that the world’s largest pharmaceutical company is willing to acquire a large rival drug company.  It even cites the CEO as saying the company real goal is to grow revenue, which is different than many other goals out there from other peers in the new market.  It also brings about the questions about who could be on the buyout target list.

Read More »

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November.  Generally you see a pattern.  This month the only pattern seems to be one of no conviction either way.  Here are the short seller reports in the short interest:

Stock (Ticker)                         NOV. 28      NOV. 14      CHANGE
Amgen Inc. (AMGN)               23,033,081   24,169,278    -4.70%
Celgene Corporation (CELG)    8,298,820    8,040,642     +3.21%
Biogen Idec Inc. (BIIB)             8,027,848    7,938,637     +1.12%
Genzyme Corporation (GENZ)  6,569,181    6,797,501     -3.36%
Gilead Sciences (GILD)           29,055,791  30,213,915    -3.83%

Jon C. Ogg
December 10, 2008

Top Pre-Market Analyst Upgrades (ANN, CVC, COF, CELG, GME, PPDI, STJ, STI, THQI, WOOF, WU)

These are some of the many research upgrades we have seen from Wall Street analysts this Monday morning with more than two hours to the open:

  • Ann Taylor (ANN) Raised to Neutral at Goldman Sachs
  • Cablevision (CVC) Raised to Hold at S&P Equity Research
  • Capital One Financial (COF) Raised to Market Perform at KBW
  • Celgene (CELG) Raised to Outperform at Baird
  • GameStop (GME) Raised to Buy at Piper Jaffray
  • Pharmaceutical Product Development (PPDI) Raised to Outperform at Baird
  • St. Jude Medical (STJ) Raised to Overweight at JPMorgan
  • SunTrust Banks (STI) Raised to Market Perform at KBW
  • THQ (THQI) Raised to Buy at Piper Jaffray
  • VCA Antech (WOOF) Raised to Buy at Piper Jaffray
  • Western Union (WU) Raised to Buy at S&P Equity Research

Jon C. Ogg
October 13, 2008

24/7 Wall St. Biotech Report: Short-Selling And Splits (AMGN)(CELG)

Windmill_2_lgShort sellers moved out of biotech stocks in the latest period according to Biohealth Investor.

The short interest in Amgen (AMGN) dropped 22% and Calgene (CELG) fell 20%.

Read More »

This Week’s BioHealth & Biotech Top Stories

We saw another exciting week full of news for key developments in drug stocks, biotech stocks, medical device stocks, and other companies involved in various aspects of health care and medicine.  Below are some of the stock tickers we covered over at BioHealthInvestor.com this week:

  • STOCK TICKERS: ABT, BSX, MDT, JNJ, SRDX, ANPI, BAYRY, MAXY, AMGN, CRA, INGN, CELG, MRK, SNY, GSK, AKRX, ARYX

This week we saw another FDA Approval in stents as Abbott’s (NYSE: ABT) XIENCE drug-eluting coronary stent was approved for marketing.  While this is causing a resurgence in stents, this space is about to become highly competitive (stocks covered: ABT, BSX, MDT, JNJ, SRDX, ANPI).  Introgen (NASDAQ: INGN) has a new twist for head and neck cancer… give it a cold, literally.  Celgene Corp. (NASDAQ: CELG) actually won out as a competitor’s bone marrow disease trials failed to meet expectations.  Merck (NYSE: MRK) was an FDA decision winner as it gets to keep its lead on the cervical cancer vaccine market in the U.S. tied up for at least 6-months longer than it was anticipated (stocks covered: MRK, SNY, GSK).

This may be a tiny company, but a patent was awarded in bone marrow and stem cell transplants.  While a biotech turned over its hemophelia treatments to a larger company, hemophelia treatments may be better off now (stocks covered: BAYRY, MAXY, AMGN).  Vaccine awards are going to keep sales up at one small vaccine maker.  One Alzheimer’s Disease treatment that originally had high hopes has bitten the dust.  P&G walked away from a partner this week, killing a tiny biotech (stocks covered: PG, ARYX).

And on the front for reviews:

  • Do you remember all the hype and hopes for synthetic blood?  This looks like the last player has gone on to greener pastures.
  • What is a good investment that has backed way off from highs that should show steady growth in the China health care sector?  We evaluated one potential company for this.

These issues are more stock issues than anything else:

Have a happy and safe LONG Fourth of July weekend.  I think there is a new treatment on the market for burnt hand trauma from fireworks, but the FDA has it on hold until next February.

Jon C. Ogg
July 4, 2008

The Week’s Top BioHealth Issues For Next Week (PFE, TEVA, CRA, IVGN, CMED, ANPI, ISRG, VVUS, CELG)

One key stock to watch next week is Pfizer Inc. (NYSE: PFE). While it has been in the land of the boring forever, watchers are looking to see if it will put in a rival bid over the $4.6 Billion Daiichi Sankyo bid from Japan for a majority stake in India’s number one generic drug maker Ranbaxy.

Speaking of Generics, Teva Pharmaceutical Industries (NASDAQ: TEVA) was weak all week after Mylan Inc. (NYSE: MYL) has signed a pact with India’s NATCO Pharma Ltd. to produce a generic version of Teva’s multiple sclerosis treatment called Copaxone.  As this  was an old favorite buy in generic investor hearts you can imagine this will be covered frequently this next week since the stock is now 15% off of its highs and closer to a 52-week low.

We know that Invitrogen (NASDAQ: IVGN) is buying Applera’s Applied Biosystems (NYSE: ABI) unit.  But what about Celera Group (NYSE: CRA)?  Traders may be looking for the "next merger candidate"and that might fit logically.

China Medical Technologies Inc. (NASDAQ: CMED) went up big on earnings news this last week and continued to rise even by the end of the week further than the initial reaction.  Technicians may have this one on a momentum screen now.

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) may be of interest after it showed some positive stent data, and its launch of QUILL may all help the perceptions next week on this small molecule company.

It’s always good to know what short sellers are targeting.  The last short selling report showed a huge drop off in the short interest compared to prior reports in large cap biotech stocks like Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Celgene Corporation (NASDAQ: CELG), and others.  FULL SHORT INTEREST DETAILS HERE.

Intuitive Surgical Inc. (NASDAQ: ISRG) was defended by William Blair this last week and shares managed to rally during the week after that news was out.  After seeing a 3-month low traders may focus here next week as a short bottom fishing attempt.

Vivus Inc. (NASDAQ: VVUS) is hanging tough after a huge gap up in its QNEXA treatment for obesity and for diabetics.  Shares barely closed down on the week, rather impressive for a small cap with a history of not holding gains.  Traders will definitely be keeping their radar eyes on this one for opportunities to buy it up or short it.

Lastly, there was a lot of news on the rheumatoid arthritis front with many companies delivering solid data for drug studies in the debilitating area from companies such as Abbott Laboratories, Array, Eli Lilly, Incyte, J&J, Schering-Plough, and Roche.  Much of the news seems overlooked by the end of a summer week, so watch these for next week.  Solid Developments for Rheumatoid Arthritis (ABT, ARRY, LLY, INCY, JNJ, SGP, RHHBY)

Jon C. Ogg
June 14, 2008

Biotech News Day (February 4, 2008) (AMAG, AOB, AMGN, CELG, MNTA, OMRI, SVA, STEM)

Below are some of the top issues affecting biotech shares today:

  • AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company developing iron compounds to treat anemia, saw shares rise 4% to $56.00 after brokerage firm Robert W. Baird initiated coverage with an OUTPERFORM rating.
  • American Oriental Bioengineering Inc. (NYSE:AOB) shares are down almost 7% at mid-day with relative high volume trading to $9.50 on no real news.
  • Amgen Inc. (NASDAQ:AMGN) stock shows no reaction to deal with Japanese drug giant Takeda Pharmaceutical. Takeda is to purchase Amgen’s Japanese unit for up to $902 million plus royalties on sales in exchange for access to 13 of Amgen’s new drugs. Amgen hopes this will curb costs and provide cash as their high-selling anemia drug sales slow due to safety issues. 
  • Celgene Corporation (NASDAQ:CELG) shares are down $1.76 to $57.94 at mid-day. Although earnings reported last Thursday met Wall Street expectations, the outlook for the success of its multiple myeloma cancer treatment, Revlimid, is mixed. Today, the company released Phase II data and news for its psoriasis drug CC-10004. The recent study showed positive results and the company announced plans to increase dosages. 
  • Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) shares continued to take a beating after they announced their earnings release date this morning. They had a rough quarter after the FDA rejected their genetic blood-thinner in November, losing about 60% of its share price. Shares are down $0.37 to $7.54 at mid-day. 
  • Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI) shares are slightly recovering today after a sharp plummet over the last 2 weeks following the FDA approval for competitor ZymoGenetics’ (ZGEN) Recothrom, that will compete with Omrix’s Evithrom in the thrombin drug market. Omrix announced last Friday that their CFO is resigning. Shares are up 4% to $21.27 on relatively heavy trading volume at mid-day. A month ago, shares were trading at over $30. 
  • Sinovac Biotech Ltd. (AMEX:SVA), the Chinese vaccine provider, has shares up over 5% to $4.11 at mid-day after Sinovec announced the private placement of 2,500,000 common shares for $9.75 million to Sansar Capital Management. 
  • StemCells Inc. (NASDAQ:STEM) stock continued to rise after news last Thursday that it plans to collaborate with Casey Eye Institute to study their leading product candidate, HuCNS-SC, a probable treatment for retinal degeneration which is a leading cause of blindness. Shares are up over 15% at mid-day to $1.77.

Rachel Lopez
February 4, 2008

The Day In Biotech Stocks (January 28, 2008) (ACOR, BIIB, CELG, PHRM, CRXX, LIPD, MDVN, PCOP)

Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis.  This data showed that Fampridine, which is designed to treat multiple sclerosis, did not increase patients’ QT interval Associated with Arrhythmia more than a placebo did.  Shares were up $4.29 at $26.07 mid-day.

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is set to report earnings after the closing bell, with First Call estimates at -$0.44 EPS on revenues of $202.58 million Shares were up less than 1% at $32.74 on the day ahead of earnings.

Carl Icahn has nominated three individuals for the board of directors in Biogen-Idec (NASDAQ: BIIB) in his activist efforts to move the shares.  Biogen-Idec shares were down $0.90 to $58.02 mid-day.

Celgene Corporation (NASDAQ: CELG) was cleared today by German regulation to proceed with its acquisition of Pharmion. Stocks are up over 3% to $53.31 at mid-day. Pharmion Corp. (NASDAQ: PHRM) shares were up 1.8% to $67.44.

CombinatoRx Inc. (NASDAQ: CRXX) shares fell almost 7% to $4.80 mid-day on thin trading volume.  Technically there was no news today, although this followed guidance last week of losses below view.

Lipid Sciences, Inc. (NASDAQ: LIPD) announced positive trial results in non-human SIV-infected primates in its proprietary deplidated autogolous virus vaccine. Share prices were up more than 15% or $0.09 to $0.65 at mid-day.

Medivation, Inc. (NASDAQ: MDVN) rose after it announced that, based on its end-of-Phase 2 meeting with the FDA, it plans to begin a pivotal confirmatory Phase III trial of Dimebon for mild-to-moderate Alzheimer’s Disease in the second quarter of 2008.  Shares rose $2.36 to $17.21 by mid-day on this data.

Pharmacopeia, Inc. (NASDAQ: PCOP) shares fell over 10% to $4.37 at mid-day on thin-trading volume. There has been no recent news.

Jon C. Ogg
January 28, 2008

Top Pre-Market Stock News (January 7, 2008)

Below is a snapshot of some of the key impact news affecting stocks in pre-market trading this Monday, January 7, 2008:

  • AllianceBernstein (AB) noted as a hidden gem in Barron’s cover story.
  • Answers Corp. (ANSW) announced a collaboration with Nokia for Series 40 and S60 mobile devices.
  • Avocet (AVCT) lowered guidance
  • Biogen-Idec (BIIB) and Elan (ELN) say that the safety data continues to support a favorable benefit-risk profile for TYSABRI.
  • Celgene Corp. (CELG) trading up 5% after guidance is in-line for 2007 and issued new guidance for 2008.
  • CNET (CNET) had a Jana Partners-led investor group take a 21% stake and try to oust the board of directors.
  • Diana Shipping (DSX) trading up almost 2% on positive Barron’s article over weekend.
  • 8X8 Inc. (EGHT) introduced a free international mobile calling plan with its new Packet8 MobileTalk trial.
  • hhgregg (HGG) reaffirmed 2008 EPS guidance of $0.95 to $1.03 vs. $1.00 est.; s-s-s up 3%.
  • JA Solar (JASO) announced a 3 for 1 stock split.
  • Jefferies (JEF) issued earnings warning.
  • Krispy Kreme (KKD) announced it has elected a new CEO.
  • Microsoft (MSFT) said at "CES" it had 100 million licenses sold of Windows Vista; 17.7 million Xbox 360’s, 10 million Xbox live users; will have new content downloads.
  • Napster (NAPS) will sell music with less copyright protection as MP3 files.
  • Nice Systems (NICE) received multi-million dollar orders from 2 of the top-3 US banks for fraud alert.
  • Rogers Communications (RCI) raised annual dividend from $0.50 to $1.00 and put 2008 revenues $11.2 to $11.5 Billion versus $11.25 Billion estimates; announced share buyback.
  • Schnitzer Steel (SCHN) missed earnings and revenue targets; stock trading down 1% so far.
  • Sony (SNE) introduces new tri-recording video Camcorder at "CES".
  • TASER (TASR) unveils its new leopard print TASER C2 personal protection device at the 2008 International Consumer Electronic tradeshow in Las Vegas today.
  • Zumiez (ZUMZ) said December s-s-s was +3.9%, but guided lower; shares down over 1%.

Jon C. Ogg
January 7, 2007

Backward & Forward, Cramer In 2007 To 2008

2007 was one volatile year and for now it appears that will be the norm for at least the start of 2008.  Everyone’s favorite market pundit or least liked pundit is obviously Jim Cramer.  If you love Cramer or can’t stand him it really doesn’t matter.  He signed a new multi-year deal with CNBC recently.  Here are some of his major calls this year that will still be referred to in 2008:

Here were Cramer’s TOP 9 STOCKS FOR 2007, with a call broken down for each one.  Borat would say HI FIVE on some and NOT SO NICE on others, as would be expected.  Cramer’s 14,582 year-end DJIA target…..Friday’s close was 13,365.87……although we did hit 14,279.96 on OCT11, 2007.  Cramer also gave a batch of price targets on most of theDJIA components:

Cramer’s Stock Picks FOR 5-YEARS OUT:

SOME LISTS: His list of recession proof stocks compared to ours.  We are updating our
Defensive Stocks For The First Half Of 2008" currently.  Cramer gave a huge list of companies he expects to benefit from the alternative energy traders (SGR, FWLT, BWA, OMG, FSLR, FTEK, WFR, TTEK, ZOLT, BP, SPWR, CY, CPST, ITRI)… Jim Cramer pondered which US companies China would want to acquire, about 3 months before sovereign funds started buying into US companies.  Cramer’s mortgage winners and losers…… Here were his MAJOR BULL MARKET STOCK PICKS(MHS, CVS, AGN, CELG, GENZ, CEPH, RIG, HAL, EMR, CAT, CMI, UTX, KO,PEP, CL, GS, SKS, VFC, UNP, CSX, BA), some of which are DJIAcomponents.  Cramer produced a "MUST OWN" list of stocks, many of whichare up significantly and some are down (WHR, BDK, ATI, BGC, HON, ASD, JCI, MDR, FWLT, CAT, TEX, DE, QCOM)

Cramer spent lots of time on International stocks that most US investors might not cover on their own.  He made a big call on Mercadolibre (MELI) (also BIDU, GOOG) with some emphasis on buying immediately, right before it made a huge run up.  Cramer’s Hidden Video Game Investment Perfect World (PWRD, ATVI, ERTS, VIA) was one he said could run more than 50% for 2008.  Cramer made 5 TOP CHINESE PICKS (CEO, CHL, SSW, FMCN, BIDU, GMR).  We’ll see in 2008 if any of his Canadian OIL TRUSTS get acquired in 2008 (BTE, CNE, PGH, PVX, PWE, AAV, GDI).  Cramer also went over his top picks from Europe for American investors (TOT, SI, ABB, PHG, BF)

ON TECHNOLOGY:  Cramer’s NEW HORSEMEN OF TECH…. will the list change in 2008???  Did Cramer Say $1,000.00 on Google, Or Is It $600.00? That was in May 2007.  Cramer Gave Monster Price targets to Baidu.com (BIDU, GOOG).. will these targets change in 2008? Cramer was very positive on all the GPS stocks,although we’d expect that Cramer will change his tune in 2008 now thatthe holiday madness is behind us (GRMN, UA, CROX, NVT, TRMB, SIRF).

Would it be fair not to include the Barron’s attack on Cramer from summer for those of you that criticize his every word?

ON WARREN BUFFETT…. Cramer noted that BROOKFIELD ASSET MANAGEMENT in Canada may be the next Berkshire Hathaway (NYSE:BRK/A) NYSE: BAM). Cramer reviewed 10 Warren Buffett stocks for analysis and then reviewed 10 More Warren Buffett stocks:

Will his buyout of ALCOA (AA) prediction come true in 2008??? Cramer gave a list of stocks that had bought back so much stock that they might be taking themselves private.

Join our free email distribution list for other Cramer calls or for updates we send out regarding IPO’s, spin-offs, restructuring, reorganization, activist investors and more.

Happy New Years from the 247WallSt.com team!

Jon C. Ogg
December 31, 2007

Biotech Short Interest NOV 2007 II (AMGN, BIIB, CELG, GENZ, GILD, IMCL, MEDX)

We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days.  Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the gains and losses were in short selling activity.  Here is the key short selling data on NASDAQ as of November 27, 2007 and Settlement Date of November 30, 2007:

STOCK (Ticker)        Shares Short    Change
Amgen (AMGN)         29,112,550      +10.89%   
Biogen Idec (BIIB)     6,648,180         (9.58%)   
Celgene (CELG)       25,751,400      +12.19%   
Genzyme (GENZ)      6,536,150        +12.36%
Gilead (GILD)            25,557,168        (1.59%)
Imclone (IMCL)          4,252,342         (13.49%)
Medarex (MEDX)        30,181,760       (7.72%)   

As a reminder, Biogen Idec was the one that Wall Street feels is close to being acquired because of its review being announced.   

Jon C. Ogg
December 11, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Celgene Proves Riskier Than Imagined (CELG)

Celgene Corp. (NASDAQ:CELG) is seeing the price of its shares crushed today after trial results were shown on Sunday at the 49th annual American Society of Hematology (ASH) Meeting of Celgene’s drug Revlimid as a treatment for a blood cancer failed to impress Wall Street.  One trial compared Revlimid combined with dexamethosone, a steroid, to only dexamethosone. The second trial combined Revlimid with two different doses of dexamethosone and the levels of complete response with total remission has failed to please.

Shares of Celgene traded down to a new 52-week low today.  Its prior range over the last year was $49.46 to $75.44, and it traded as low as $47.21 today.  Shares are currently down about 14% at $49.35 and the stock has traded over 26 million shares.

Since October, shares of Celgene have now lost 1/3 of their value, and its market cap is still over $19 Billion.  Prior to today, analysts estimates from First Call put the entire 2008 revenues at $2.06 Billion.  Prior to today’s stock sale the average analyst price target was over $75.00.  Wachovia just assigned a new Outperform rating to it last week, and in the two weeks prior it had been upgraded at BMO Capital Markets and at Banc of America.

This had previously been a Cramer pick as well and he’s even interviewed the CEO before.  Cramer has also evaluated this one before with other biotech blow-ups.

 

Jon C. Ogg

December 10, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.